The Wall Street Journal
Industry Snippets: The Wall Street Journal - A Big, Fatty Opportunity for Big Pharma
The Wall Street Journal

There was a significant article (see link below) on NASH in the Saturday's WSJ’s Heard on the Street column.  Allergan, Gilead and Intercept are mentioned and $40 billion is cited by Optum as potential peak world-wide sales.

A Big, Fatty Opportunity for Big Pharma